Skip to main content
Brittany (Knick) Ragon, MD, Hematology, Charlotte, NC

BrittanyKnick(Knick)RagonMD

Hematology Charlotte, NC

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Clinical Informatics

Associate Professor/Adult Leukemia and Transplant Specialist

Dr. Ragon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ragon's full profile

Already have an account?

  • Office

    1021 Morehead Medical Dr
    Ste A
    Charlotte, NC 28204
    Phone+1 980-442-2000

Summary

  • Dr. Brittany Ragon is a hematologist/medical oncologist in Charlotte, NC. She received her medical degree from University of South Carolina School of Medicine, trained at Vanderbilt University Medical Center and the MD Anderson Cancer Center, and has been in practice 8 years. She specializes in hematologic oncology and cellular therapy and is experienced in leukemia, stem cell transplantation, myeloproliferative disorders, myelodysplastic syndromes, and clinical informatics.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
  • University of South Carolina School of Medicine
    University of South Carolina School of MedicineClass of 2011
  • Clemson University
    Clemson UniversityBS, Biosystems Engineering, Minor Bioengineering, Summa Cum Laude, 2003 - 2007

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2017 - 2025
  • TX State Medical License
    TX State Medical License 2015 - 2018
  • TN State Medical License
    TN State Medical License 2013 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Alpha Omega Alpha Honor Society Junior AOA, 2010
  • Algernon Sydney Sullivan Award 2007
  • Calhoun Scholar—Awarded B.C. Inabinet Honors Medallion 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias  
    Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNar..., American Journal of Hematology, 9/27/2016
  • Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategy  
    Ragon BK, Clifton C, Chen H, Savani B, Englehardt B, Kassim A, Jagasia M, Bio Blood and Marrow Transplant., 1/1/2014
  • Penetrance of Hemochromatosis in HFE Genotypes Resulting in pCys282Tyr and p[Cys282Tyr];[His63Asp] in the eMERGE Network  
    Gallego C, Burt A, Sundaresan A, Shaw C, Crosslin D, Crane P, Fullerton S, Hansen K, Carrell D, Kuivaniemi H, Derr K, Zi Y, Andrade M, McCarty C, Kitchner T, Ragon BK,..., Am J Hum Genet., 1/1./2015
  • Join now to see all

Abstracts/Posters

  • BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
    Brittany K Ragon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
    Brittany K Ragon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Network based proteomic profiling of leukemia and myelodysplasia defines protein expression signatures and suggests targeted therapy combinations.
    Kornblau S, Hu C, Hoff F, Ragon BK, Qiu Y, Zhang N, Yoo SY, Coombes K, Horton T, Qutub A, Global Reverse Phase Protein Array Workshop, 1/1/2016
  • Join now to see all

Lectures

  • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukemia. 
    Houston, TX - 1/1/2016
  • Amyloidosis: “X” marks the spot. 
    Houston, TX - 1/1/2015
  • TPMT Deficiency 
    Houston, TX - 1/1/2015
  • Join now to see all

Press Mentions

  • Levine Cancer Institute Specializes Atrium's Hospital-at-Home Model - Charlotte Business Journal
    Levine Cancer Institute Specializes Atrium's Hospital-at-Home Model - Charlotte Business JournalMarch 30th, 2021
  • Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD
    Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MDJanuary 24th, 2024

Grant Support

  • Leukemia Research Foundation New Investigator GrantLeukemia Research Foundation2018–2019
  • NIH T32 Training GrantNIH2015–2017

Professional Memberships